Media stories about Axovant Sciences (NASDAQ:AXON) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.8815017192886 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant (finance.yahoo.com)
- Glowing Stock’s Review – Axovant Sciences Ltd (NASDAQ: AXON) – Stocks Pen (stockspen.com)
- Stock to Watch – Axovant Sciences Ltd., (NASDAQ: AXON) – Stock Watch (stocksnewstimes.com)
- Buy or Sell Recommendation?: Axovant Sciences Ltd. (AXON) – Nasdaq Chronicle (nasdaqchronicle.com)
- Axovant Sciences Ltd (AXON) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
Axovant Sciences (AXON) traded down $0.02 during midday trading on Friday, reaching $1.43. 496,966 shares of the company’s stock traded hands, compared to its average volume of 1,568,117. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 0.45. Axovant Sciences has a 12 month low of $1.40 and a 12 month high of $27.98. The firm has a market cap of $160.60, a PE ratio of -0.62 and a beta of -0.46.
In other news, Director George Bickerstaff purchased 25,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was bought at an average price of $1.50 per share, for a total transaction of $37,500.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 72.40% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.